Articles On Proteomics International Laboratories (ASX:PIQ)

Proteomics International Laboratories (ASX:PIQ) has announced that a study demonstrating the clinical utility of the PromarkerD test in predicting diabetic kidney disease has been published in the journal PLOS ONE.

The ASX is poised to open Monday 0.70% higher Wall Street had its best month in July since November 2020 Ahead this week, the RBA’s meeting on Tuesday Local shares are set to open higher today. At 8am AEDT, the ASX 200 August futures is p...

Ask A Fund Manager The Motley Fool chats with the best in the industry so that you can get an insight into how the professionals think. In this edition, Alto Capital investment advisor Tony Locantro talks about why he loves three ASX share...

Ask A Fund Manager The Motley Fool chats with the best in the industry so that you can get an insight into how the professionals think. In this edition, Alto Capital investment advisor Tony Locantro discusses two ASX shares that are ready...

The ASX is set to open slightly lower on Monday US social media stocks tumbled on Friday, with Snap plunging by 39% Ahead this week, US Fed’s rate decision and Australia’s June quarter CPI Local shares are set to dip on Monday, with the A...

Proteomics International’s (PIQ) European patent protection for its PromarkerD predictive test has been expanded to cover pre-diabetes The test can now diagnose individuals who are pre-diabetic and asymptomatic for kidney disease, while t...

The prospect of a simple blood test rather than an invasive surgical procedure to detect a painful gynaecological condition has taken a step forward following a study by Proteomics International Laboratories.

Proteomics International Laboratories (PIQ) reports an initial positive diagnostic readout of its endometriosis clinical validation study Initial results show several plasma proteins are “statistically significant” biomarkers for endometri...

Proteomics International Laboratories (PIQ) secures a worldwide licence for oesophageal cancer biomarkers The licence agreement to commercialise biomarkers that test for oesophageal adenocarcinoma has been signed with the QIMR Berghofer Me...

ResApp’s independent study of cough app falls short Recce Pharma completes Cohort 6 dosage in Phase 1 trial Proteomics secures exclusive biomakers license Smartphone-based respiratory diagnostic maker, ResApp Health (ASX:RAP), plunged by...

ASX is set open higher today with Wall Street on holidays overnight European stocks rallied RBA governor Phil Lowe will make a speech later today Wall Street was closed on Monday to mark Juneteenth, an annual commemoration of the end of s...

Proteomics International Laboratories has passed a milestone in its drive to commercialise its PromarkerD test that predicts diabetic kidney disease with a successful pilot batch of key test components.

Proteomics has completed a manufacturing technology transfer of its PromarkerD test Genetic Technologies build model that could create pathway in the US Proteomics proves it can produce the PromarkerD tests at scale Proteomics Internation...

Proteomics International Laboratories (PIQ) has produced a pilot batch of PromarkerD test components to predict the onset of diabetic kidney disease The products were produced through a collaboration with specialist immunoassay manufacture...

A new study shows Proteomics International Laboratories’ proven diagnostic test for diabetic kidney disease, PromarkerD, has the potential to predict late-stage renal decline in addition to its early-onset.

Medical technology company Proteomics International Laboratories has taken another step on its 10-year journey to get PromarkerD, its ground-breaking predictive blood test for kidney diabetes, to market.

Race Oncology is set to commence Phase 1 study of Zantrene after being given governance approval Rhythm Biosciences has filed blood test ColoSTAT with the TGA Proteomics gets $400k government funding Race Oncology (ASX:RAC) has just recei...

Proteomics International (PIQ) is awarded over $400,000 in funding to manufacture its predictive diagnostic test for diabetic kidney disease The company receives the funds from MTPConnect to develop its PromarkerD clinical diagnostic test...

Proteomics International establishes world class Clinical Advisory Board promarkerd.com/clinical-advisory-board Comprises highly-respected physicians specialising in diabetes and kidney disease care from the United States, Europe and...

Chimeric wants to accelerate its clinical trial readiness via a deal with WuXi Recce advances to higher dosing in Phase I clinical trial Proteomics engages experts to advance commercialisation Chimeric signs deal with WuXi Cell therapy sp...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Here’s something for anyone who...

The ASX 200 Health Index (XHJ) and the benchmark ASX 200 are trading flat today. Proteomics advances on blood test results Investors gave Proteomics International Laboratories (ASX:PIQ) the thumbs up after the company said it has identified...

Proteomics International Laboratories (PIQ) completes a study targeting oesophageal adenocarcinoma cancer Proteomics International and QIMR Berghofer are collaborating on the development of a simple blood test for oesophageal adenocarcinom...

ASX to fall as Meta crash derails Tech rebound Local shares are expected to open lower this morning as a Meta (née Facebook) crash overnight derailed the Wall Street rebound. Meta plunged by 26% after reporting a decline in daily active use...

The ASX 200 Health Index (XHJ) has dropped by almost 5% at the time of writing, compared to the broader index which is down by 0.20%. Healthcare giant and blood specialist, CSL (ASX:CSL), which makes up a large part of the ASX Healthcare in...

Wall Street rallies on Fed decision US stocks rallied strongly overnight, as investors digested the central bank’s decision to speed up its tapering program and hike rates next year. Fed Reserve governor Jerome Powell said the bank will red...

Proteomics International Laboratories (PIQ) sees its cash reserves strengthened by a $1.2 million research and development tax incentive for the 2020/2021 financial year During FY21 Proteomics spent $2.85 million on R&D, enabling the c...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

World’s first predictive diagnostic test for diabetic kidney disease to be sold in Great Britain under distribution deal with global diagnostic distributor, Apacor Limited Apacor will become the exclusive distributor for PromarkerD...

Proteomics International Laboratories (PIQ) signs a deal with medical diagnostics company Apacor to bring its PromarketD test to Britain PromarkerD is a biomarker-based blood test that predicts kidney function decline in type 2 diabetes Th...

Study shows PromarkerD is significantly better than current standard of care tests eGFR and ACR for predicting future decline in kidney function in patients with type 2 diabetes PromarkerD correctly identified 84% of patients with n...

Wall Street sets record highs for fifth consecutive day US stocks closed their fifth consecutive day at all time highs, as weekly jobless claims continue to head in the right direction. The S&P 500 rose by 0.42% and the Nasdaq was up 0....

Proteomics International Laboratories (PIQ) says study results show PromarkerD is superior to the current standard of care tests for predicting future kidney function decline in type 2 diabetes The company says its trial of 850 patients de...

Proteomics International Laboratories (PIQ) has been awarded a $100,000 voucher to manufacture clinical diagnostic tests in Western Australia The funding from the MTPConnect WA Life Sciences Innovation Hub MTP will go towards producing Pro...

It’s been a busy morning for the ASX Healthcare sector, with plenty of positive announcements for investors to digest. But the Health Index (XHJ) is trading down by 0.5% at the time of writing, compared to the broader index which is trading...

BRISBANE, Australia, Aug. 12, 2021 /PRNewswire/ — Treatment with diabetes drug canagliflozin lowers the PromarkerD risk score for developing diabetic kidney disease in patients with type 2 diabetes, latest research suggests. In a study pres...

Summary  The Australian benchmark index, ASX200, added 4 points to close at fresh closing high of 7,588. The index gained as much as 0.3% to hit an intraday high of 7,608.6 during the session.  Agro-based company GrainCorp topped the...

Proteomics International Laboratories (ASX:PIQ) has announced it has contracted French immunoassay specialist Biotem to manufacture test kits for the PromarkerD predictive test for diabetic kidney disease.

Summary REA Group (ASX:REA) completes transaction with PropertyGuru BNK Banking (ASX:BBC) announces alliance with Goldman Sachs for A$500m Securitisation Warehouse Westpac (ASX:WBC) to kick-off jab program for Western Sydney The S...

Summary Benchmark index, the ASX 200, hit a record high of 7,509.2 this morning. The market was supported by gains in blue-chip miners BHP and Rio, as well as banking majors. Seven of 11 sectors traded in green, while material and ene...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

Australian shares have extended gains for the second day in a row, rising by 0.91% despite more COVID cases across states. All 11 sectors were in the green, except for Healthcare. Mining and Energy led the gains, rising by 2% each, buoyed b...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

Proteomics International Laboratories says a retrospective study has found diabetes patients using treatment drug, canagliflozin, returned scores indicating they were statistically at lower risk of developing kidney disease by using Proteom...

The Proteomics International Laboratories Ltd (ASX: PIQ) share price has jumped firmly into the green today. Shares in the Australian biotech company surged this morning and jumped 10% from the market open, before retreating back down. At...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

The Proteomics International Laboratories Ltd (ASX: PIQ) share price won’t be going anywhere today. Shares in the biotech company were placed in a trading halt late yesterday. Let’s take a look at why the company’s shares are at a halt and...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Theme of the week Healthcare fi...

Australian shares appeared to shrug off the latest COVID-19 lockdowns for much of the day, but ultimately closed lower on the day. The ASX200 finished 0.01 per cent down at 7,307, while the ASX Emerging Companies Index fell 1.22 per cent, c...